Galapagos Signs new Compound Management Agreement with Sepracor
Complete the form below to unlock access to ALL audio articles.
Galapagos NV has announces that its service division BioFocus DPI will provide compound management and related services to Sepracor Inc., a company providing respiratory and central nervous system disorder medicines.
Total contract value for Galapagos is €1 million ($1.5 million). Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor’s proprietary compound library, and plate and replicate these compounds for a period of three years. Services will be provided by BioFocus DPI’s compound management facility in South San Francisco, USA.
“We welcome Sepracor as a new client to BioFocus DPI,” said Onno van de Stolpe, Chief Executive Officer of Galapagos. “Our compound management site has been able to broaden its customer base over the last year, and with this agreement we further expand our list of pharma companies.”
